TABLE 1.
Incidences of cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) of chimeric antigen receptor T‐cell (CAR‐T) cell therapy overviewing 5 years' researches
| Trial registration | Disease | Target | CRS% | sCRS% | ICANS% | sICANS% | Time | Journal | |
|---|---|---|---|---|---|---|---|---|---|
| Cilta‐cel | NCT03548207 | MM | BCMA | 95 | 4 | 21 | 9 | 2021 | The Lancet |
| Relma‐cel | NCT04089215 | LBCL | CD19 | 47.50 | 5.10 | 20.30 | 5.10 | 2021 | Cancer Medicine |
| 4SCAR19 | ChiCTR‐OOC‐16007779 | NHL | CD19 | 14 | 0 | 4.76 | 4.76 | 2020 | Frontiers in Immunology |
| UCART19 | NCT02808442 and NCT02746952 | B‐ALL | CD19 | 91 | 14 | 38 | 0 | 2020 | The Lancet |
| LV20.19 | NCT03019055 | B cell malignancy | CD19/CD20 | 64 | 5 | 32 | 14 | 2020 | Nature Medicine |
| NCT04689659 | T‐ALL | CD7 | 90 | 10 | 15 | 0 | 2021 | Journal of Clinical Oncology | |
| HuCART19 | NCT02374333 | B‐ALL | CD19 | 84 | 6.80 | 39 | 4 | 2021 | Journal of Clinical Oncology |
| KTE‐X19 | NCT02614066 | B‐ALL | CD19 | 89 | 24 | 33 | 25 | 2021 | The Lancet |
| NCT01593696 | B‐ALL | CD19 | 100 | 30 | 20 | 8 | 2021 | Journal of Clinical Oncology | |
| Ide‐cel | NCT03361748 | MM | BCMA | 84 | 5 | 18 | 3 | 2021 | The New England Journal of Medicine |
| Liso‐cel | NCT02631044 | LBCL | CD19 | 42 | 2 | 30 | 10 | 2020 | The Lancet |
| Axi‐cel | non‐trial | B‐NHL | CD19 | 93 | 16 | 70 | 35 | 2020 | Journal of Clinical Oncology |
| Axi‐cel | NCT03153462 | LBCL | CD19 | 91.20 | 7 | 68.70 | 31 | 2020 | Journal of Clinical Oncology |
| NCT01747486 | CLL | CD19 | 63 | 24 | 40.63 | 9.38 | 2020 | Journal of Clinical Oncology | |
| NCT0231561 | B‐ALL | CD22 | 86.20 | 20.30 | 32.80 | 1.70 | 2020 | Journal of Clinical Oncology | |
| KTE‐X19 | NCT02601313 | MCL | CD19 | 91 | 15 | 63 | 31 | 2020 | The New England Journal of Medicine |
| Tisagenlecleucel | B‐ALL | CD19 | 94 | 18 | 40 | 6 | 2020 | Journal of Clinical Oncology | |
| Bb2121 | NCT02658929 | MM | BCMA | 76 | 6 | 42 | 3 | 2019 | The New England Journal of Medicine |
| Axi‐cel | NCT02348216 | LBCL | CD19 | 91.74 | 11 | 66.01 | 32 | 2019 | The Lancet Oncology |
| Tisagenlecleucel | NCT02445248 | DLBCL | CD19 | 58 | 22 | 21 | 12 | 2019 | The New England Journal of Medicine |
| NCT01044069 | B‐ALL | CD19 | 85 | 26 | 44 | 42 | 2018 | The New England Journal of Medicine | |
| Axi‐cel | NCT02435849 | B‐ALL | CD19 | 77 | 47 | 40 | 13 | 2018 | The New England Journal of Medicine |
| Axi‐cel | NCT02348216 | LBCL | CD19 | 93 | 13 | 64 | 28 | 2017 | The New England Journal of Medicine |
| CTL019 | NCT02030834 | B cell lymphoma | CD19 | 57 | 18 | 39 | 11 | 2017 | The New England Journal of Medicine |
| NCT01865617 | CLL | CD19 | 83 | 8 | 33 | 25 | 2017 | Journal of Clinical Oncology |